Supplementary Figure 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Autor: Deborah Ricci, George Mulligan, Dixie-Lee Esseltine, Andrew Cakana, Pier Luigi Zinzani, Ofer Shpilberg, Michael Crump, Sven de Vos, Joanna Romejko-Jarosinska, Adriana Teixeira, Simon Rule, Fritz Offner, Jiri Mayer, Adriana Scheliga, Xiaonan Hong, Evgenii A. Osmanov, Michael E. Schaffer, Helgi van de Velde, Yusri A. Elsayed, Panteli Theocharous, Alice Shapiro, Dana Gaffney, Reyna Favis, Jayaprakash D. Karkera, Erin D. Henitz, Weimin Li, Bertrand Coiffier
Rok vydání: 2023
DOI: 10.1158/1078-0432.22448850
Popis: Supplementary Figure 3 PDF file 78K, Kaplan-Meier distributions of A) PFS and B) OS under the G-dominant genetic model for PSMB1 P11A among all patients evaluable for the biomarker pair of PSMB1 P11A genotype and CD68 expression who had low (≤50 CD68-positive cells) CD68 expression
Databáze: OpenAIRE